The unfolded protein response (UPR) is a conserved cellular stress network activated when the endoplasmic reticulum (ER) accumulates misfolded or unfolded proteins. In myositis, a group of inflammatory myopathies characterized by immune-mediated muscle injury, ER stress is increasingly recognized as a mechanistic bridge linking immune activation, protein quality control failure, and maladaptive cell survival programs. The ER functions as a specialized organelle for protein folding, post-translational modification, and quality control, including calcium homeostasis and redox regulation. When the folding capacity is overwhelmed—by inflammatory cytokines, oxidative stress, viral triggers, or impaired proteostasis—misfolded proteins accumulate, generating ER stress and initiating the UPR.
At the molecular level, ER stress signals through three canonical UPR sensors: IRE1 (inositol-requiring enzyme 1), PERK (PKR-like ER kinase), and ATF6. Their activation shifts the cell from a growth-and-secretion mode to an adaptive maintenance mode. A central early event is mediated by PERK, which phosphorylates the translation initiation factor eIF2α (eukaryotic initiation factor 2 alpha). Phosphorylated eIF2α reduces global protein synthesis, thereby decreasing the influx of nascent polypeptides into the ER. This translational attenuation is protective in the short term because it lowers the folding burden. However, sustained or excessive ER stress can convert adaptive pathways into pro-apoptotic signaling, leading to muscle fiber degeneration and amplifying inflammation.
UPR signaling also enhances ER-associated degradation (ERAD) and autophagy. Through IRE1 activation, splicing of XBP1 (X-box binding protein 1) upregulates chaperones and components of the secretory quality control machinery. IRE1 can also activate pro-inflammatory branches via regulated mRNA decay and signaling intermediates, potentially intersecting with innate immune pathways. ATF6 translocates to the Golgi for proteolytic cleavage, then acts as a transcriptional driver of ER chaperones and stress response genes. Together, these programs attempt to restore proteostasis by increasing folding capacity and clearing aberrant proteins.
In myositis, several converging mechanisms may drive persistent ER stress. Inflammatory cytokines such as interferon-γ and tumor necrosis factor–α can disrupt ER homeostasis and increase protein misfolding. Oxidative stress and mitochondrial dysfunction in inflamed muscle further impair redox-dependent folding reactions. Additionally, antigen processing and immune recognition are tightly coupled to ER function, and altered ER stress signaling can influence expression of major histocompatibility complex (MHC) molecules and chemokine profiles. As a result, UPR activation is not merely a consequence of muscle injury; it may actively shape the immune microenvironment and determine whether cells survive, enter senescence-like states, or undergo apoptosis.
Clinically, ER stress/UPR involvement is relevant because it offers mechanistic targets beyond broad immunosuppression. Therapeutic strategies under investigation in related inflammatory and metabolic diseases aim to modulate specific arms of the UPR. For example, controlling maladaptive PERK–eIF2α signaling could, in theory, rebalance protein synthesis attenuation with recovery. Targeting IRE1 RNase activity or downstream XBP1 signaling may reduce chronic stress outputs and pro-inflammatory signaling. Enhancing adaptive proteostasis via chemical chaperones, upregulating ERAD, or supporting autophagy could restore protein folding capacity and reduce cellular damage.
Biomarker research is also important. Components of the UPR pathway—such as phosphorylated eIF2α, spliced XBP1, and ER chaperones—may serve as indicators of cellular stress load and treatment response. In muscle biopsies and patient-derived cells, correlating UPR activation with histopathologic features (endomysial inflammation, interferon signatures, microvascular injury) could refine patient stratification. Such biomarkers may help distinguish phenotypes in which ER stress is dominant versus those in which immune pathways predominate.
Finally, it is essential to recognize that UPR is dose- and time-dependent. Transient activation promotes survival and repair, whereas chronic activation can trigger apoptosis through pathways involving C/EBP homologous protein (CHOP) and other stress mediators. Therefore, therapeutic goals should prioritize restoring homeostasis rather than fully blocking protective stress responses. A balanced approach—reducing upstream drivers (inflammation, oxidative stress) while selectively moderating maladaptive UPR outputs—may be the most rational path.
Source: @dr_immuno29 (ER Stress & UPR in Myositis—Made Simple)
Dr.Mukesh , MD , DM: 🧬 ER Stress & UPR in Myositis—Made Simple Think of the endoplasmic reticulum (ER) as the cell’s protein factory. 🔹 Too many misfolded proteins → ER stress 🔹 Cell activates the Unfolded Protein Response (UPR) to survive: ✅ ⬇️ Reduce new protein synthesis (PERK–eIF2α) ✅ 🛠️. #breaking
— @dr_immuno29 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
